Zotiraciclib diHCl, also known as TG-02 or SB-1317, is a small molecule inhibitor primarily targeting cyclin-dependent kinases (CDKs), particularly CDK7 and CDK9, which play crucial roles in cell cycle regulation and transcriptional control. This compound is characterized by its ability to interfere with the phosphorylation of RNA polymerase II, thereby inhibiting transcriptional elongation and promoting apoptosis in cancer cells. Zotiraciclib diHCl is typically presented as a dihydrochloride salt, enhancing its solubility and bioavailability for therapeutic applications. It has been investigated in various preclinical and clinical studies for its potential efficacy in treating different types of malignancies, particularly those characterized by dysregulated CDK activity. The compound's mechanism of action, alongside its selectivity for specific CDKs, positions it as a promising candidate in the field of targeted cancer therapies. As with many investigational drugs, ongoing research is essential to fully elucidate its pharmacokinetics, safety profile, and therapeutic potential in clinical settings.

Zotiraciclib, also known as TG02 and  SB1317, is a novel small molecule potent CDK/JAK2/FLT3 inhibitor.  Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, with 80 percent of glioblastomas characterized by this property.

Zotiraciclib diHCl (TG-02, SB-1317)

1354567-82-0: Zotiraciclib diHCl, also known as TG-02 or SB-1317, is a small molecule inhibitor primarily targeting cyclin-dependent kinases (CDKs), particularly CDK7 and CDK9, which play crucial roles in cell cycle regulation and transcriptional control. This compound is characterized by its ability to interfere with the phosphorylation of RNA polymerase II, thereby inhibiting transcriptional elongation and promoting apoptosis in cancer cells. Zotiraciclib diHCl is typically presented as a dihydrochloride salt, enhancing its solubility and bioavailability for therapeutic applications. It has been investigated in various preclinical and clinical studies for its potential efficacy in treating different types of malignancies, particularly those characterized by dysregulated CDK activity. The compound's mechanism of action, alongside its selectivity for specific CDKs, positions it as a promising candidate in the field of targeted cancer therapies. As with many investigational drugs, ongoing research is essential to fully elucidate its pharmacokinetics, safety profile, and therapeutic potential in clinical settings.

<p>Zotiraciclib (TG02/SB1317) is a CDK/JAK2/FLT3 inhibitor potentially treating Myc-overexpressing cancers, including glioblastoma.</p>

CAS 1354567-82-0

Zotiraciclib diHCl (TG-02, SB-1317)

Zotiraciclib HCl

Ref: TM-T70897